Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1502-1510

  Lee, Jae Jung ^a   Kim, Soyeon ^a   Young, Il Yeom ^b   Dae, Seog Heo ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Cervical cancer; E2F1; Gene therapy; HPV E6; p63 ; p73 ; p73 ; Tumor specific promoter

Indexed keywords

ADENOVIRUS VECTOR; ANTIBIOTIC G 418; P63 PROTEIN ALPHA; P63 PROTEIN GAMMA; P73 PROTEIN ALPHA; P73 PROTEIN BETA; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA TUMOR VIRUS; ENDOTHELIUM CELL; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; KERATINOCYTE; PROMOTER REGION; PROTEIN EXPRESSION; SAFETY; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS RECOMBINANT; WART VIRUS;

EID: 33846980459     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3300     Document Type: Article

References (53)

1. Levrero M, De Laurenzi V, Costanza A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113:1661-70.
2. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
3. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
4. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
5. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399:806-9.
6. Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19:3126-30.
7. Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20:3193-205.
8. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998; 58:5061-5.
9. Shimada A, Kato S, Enjo K, et al. The transcriptional activities of p53 and its homologue p51/p63: Similarities and differences. Cancer Res 1999; 59:2781-6.
10. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73.
11. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: Development and cancer. Trends Biochem Sci 2003; 28:663-70.
12. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-64.
13. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6:55-61.
14. Lu W, Lin J, Chen J. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 2002; 62:1305-10.
15. Rodicker F, Putzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003; 63:2737-41.
16. Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 2003; 22:8394-402.
17. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001; 11:23-30.
18. Ben-Israel H, Kleinberger T. Adenovirus and cell cycle control. Front Biosci 2002; 7:d1369-95.
19. Tommasino M, Accardi R, Caldeira S, et al. The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003; 21:307-12.
20. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin Jr WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998; 18:6316-24.
21. Wienzek S, Roth J, Dobbelstein M. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53. J Virol 2000; 74:193-202.
22. Roth J, Dobbelstein M. Failure of viral oncoproteins to target the p53-homologue p51A. J Gen Virol 1999; 80:3251-5.
23. Schoell WM, Janicek MF, Mirhashemi R. Epidemiology and biology of cervical cancer. Semin Surg Oncol 1999; 16:203-11.
24. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32:S59-66.
25. Lim MJ, Min SH, Lee JJ, et al. Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. Mol Ther 2006; 13:899-909.
26. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1:199-207.
27. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277:2674-81.
28. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188:1763-8.
29. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
30. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21:182-91.
31. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. Embo J 1987; 6:139-44.
32. Ku JL, Kim WH, Park HS, Kang SB, Park JG. Establishment and characterization of 12 uterine cervical-carcinoma cell lines: Common sequence variation in the E7 gene of HPV-16-positive cell lines. Int J Cancer 1997; 72:313-20.
33. Cole ST, Streeck RE. Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer. J Virol 1986; 58:991-5.
34. Riccioni T, Cirielli C, Wang X, Passaniti A, Capogrossi MC. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Ther 1998; 5:747-54.
35. Fujisawa M, Shirakawa T, Fujioka H, et al. Adenovirus-mediated p53 gene transfer to rat testis impairs spermatogenesis. Arch Androl 2001; 46:223-31.
36. Davis BB, Dong Y, Weiss RH. Overexpression of p73 causes apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2003; 284:C16-23.
37. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol 1992; 66:4757-62.
38. Ho JW, Song JZ, Leung YK. Activation of p53 by specific agents in potential cancer therapy. Curr Med Chem Anti-Canc Agents 2005; 5:131-5.
39. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999; 18:1131-8.
40. Gervais JL, Seth P, Zhang H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 1998; 273:19207-12.
41. Hoppe-Seyler F, Butz K. Molecular mechanisms of virus-induced carcinogenesis: The interaction of viral factors with cellular tumor suppressor proteins. J Mol Med 1995; 73:529-38.
42. Hwang SG, Lee D, Kim J, Seo T, Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem 2002; 277:2923-30.
43. Huh WK, Gomez-Navarro J, Arafat WO, et al. Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix. Gynecol Oncol 2001; 83:370-7.
44. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen SL. Adenovirus-mediated p21(WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 1999; 73:4983-90.
45. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56:3047-54.
46. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 1998; 13:5-9.
47. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61:813-7.
48. Jee YS, Lee SG, Lee JC, et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 2002; 22:2629-34.
49. Das S, Nama S, Antony S, Somasundaram K. p73 beta-expressing recombinant adenovirus: A potential anticancer agent. Cancer Gene Ther 2005; 12:417-26.
50. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997; 3:1145-9.
51. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: Potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002; 62:3438-47.
52. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88:5523-7.
53. Natesan S, Rivera VM, Molinari E, Gilman M. Transcriptional squelching reexamined. Nature 1997; 390:349-50.